CorMedix (NASDAQ:CRMD) Earns Outperform Rating from Analysts at Oppenheimer

Posted by George Bondi on Sep 23rd, 2026

Equities research analysts at Oppenheimer started coverage on shares of CorMedix (NASDAQ:CRMD – Get Free Report) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $15.00 price target on the stock. Oppenheimer’s price objective would suggest a potential upside of 92.80% from the stock’s previous close.

CRMD has been the topic of a number of other reports. Weiss Ratings reissued a “hold (c)” rating on shares of CorMedix in a research note on Tuesday, August 11th. Royal Bank Of Canada upped their target price on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Get Our Latest Report on CRMD

CorMedix Trading Up 0.1%

CRMD opened at $7.78 on Wednesday. The stock has a market capitalization of $606.37 million, a price-to-earnings ratio of 3.64 and a beta of 1.50. The company has a quick ratio of 2.36, a current ratio of 2.56 and a debt-to-equity ratio of 0.31. CorMedix has a twelve month low of $6.13 and a twelve month high of $13.02. The company has a 50-day simple moving average of $7.94 and a 200 day simple moving average of $7.78.

CorMedix (NASDAQ:CRMD – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.24 by $0.05. CorMedix had a net margin of 40.49% and a return on equity of 40.52%. The firm had revenue of $101.93 million for the quarter, compared to analyst estimates of $96.04 million. Analysts predict that CorMedix will post 0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On CorMedix

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of CorMedix during the second quarter worth about $49,644,000. Bank of New York Mellon Corp bought a new stake in CorMedix during the 2nd quarter worth approximately $3,108,000. Pacer Advisors Inc. raised its stake in shares of CorMedix by 128.7% in the first quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock worth $3,942,000 after purchasing an additional 326,724 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of CorMedix by 150.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock worth $3,443,000 after purchasing an additional 263,618 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in shares of CorMedix in the second quarter valued at approximately $1,909,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc is a biopharmaceutical company focused on developing and commercializing products designed to prevent and treat infectious and inflammatory complications associated with medical devices and procedures. The company’s lead product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution intended to help reduce catheter-related bloodstream infections in adult patients receiving chronic hemodialysis through central venous catheters.

DefenCath was approved by the U.S.